by clicking the arrows at the side of the page, or by using the toolbar.
by clicking anywhere on the page.
by dragging the page around when zoomed in.
by clicking anywhere on the page when zoomed in.
web sites or send emails by clicking on hyperlinks.
Email this page to a friend
Search this issue
Index - jump to page or section
Archive - view past issues
Wool Stocktake : AWI Annual Report 2013-14
$1,100,000 project expenditure + 2.8 AWI staff (full time equivalent) Investment activities will largely involve partnership with credible research institutions around the globe in conduct of consumer-based research evaluating the comparative benefits of wool in the areas of: Sleep quality and quantity -- sleeping on or under wool bedding, or in wool (sleepwear). Dermatology -- challenging the widespread misconception that wool is an allergen, and demonstrating that suitably selected fine Merino products are healthy for the skin, especially for those with the most sensitive skin. Flammability -- demonstration of wool s inherent flame retardance properties in support of product development and marketing opportunities. As a complement to these efforts, investments will address the development of technical specifications for trading and assurance of product qualities where these address wellness attributes of wool products. Complete and communicate to technical and trade audiences research that: Unequivocally demonstrates that wool is not an allergen. Activity has focussed on joint conduct with IWTO of a strategic review of wool and human wellness outcomes. Demonstrates the role of fine Merino baselayers in ameliorating chronic skin conditions associated with microclimate management of the skin, such as atopic dermatitis. Progress in establishment of follow-on clinical studies has been slower than hoped, due in-part to slow ethics approval processes. Supports the recognition of wool bedding as part of a healthy night s sleep, and development of Merino sleepwear and maternity-wear markets. Publication development has progressed well, and good progress occurred in attracting international co- funding in development and evaluation of Merino sleepwear. Supports development of product market opportunities in categories such as corporate wear, safety wear, medical products and infantswear. Effort has focussed on establishment of Merino sleepwear as a market, and digital assets attesting to wool s flame resistance properties. Skin health: Following the initial successful pilot clinical trial involving 30 adult patients conducted during 2012/13 at Queensland Institute of Dermatology (QID), follow-on clinical trials were established at QID (adults/youth) and Murdoch Childrens Research Institute (infants). Commencement of these trials was slower than hoped, due to slow ethics committee approval processes. Other effort has focussed on completion and submission of peer-reviewed science publication arising from the QID Phase 1 research, and successfully exploring international research and co-funding opportunities. Sleep: Follow-on trial was established with La Trobe University (children s sleep), and one science publication was submitted by each of University of Sydney and La Trobe University, with two additional publications in preparation, and the doctoral thesis of Mirim Shin nearing completion. Queensland Institute of Dermatology research leader Dr Lynda Spelman with Teagan Holland and Kurt Davidson examining Merino apparel used in their skin health study. REPORT OF 2013/14 OPERATIONS -- OFF-FARM R&D
AWI Annual Report 2014-15
AWI Annual Report 2012-13